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Abstract: ETV6 gene abnormalities are well described in tumor
pathology. Many fusion partners of ETV6 have been reported in
a variety of epithelial, mesenchymal, and hematological malig-
nancies. In salivary gland tumor pathology, however, the
ETV6-NTRK3 translocation is speciﬁc for (mammary analog)
secretory carcinoma, and has not been documented in any other
salivary tumor type. The present study comprised a clinical,
histologic, and molecular analysis of 10 cases of secretory
carcinoma, with typical morphology and immunoproﬁle har-
boring a novel ETV6-RET translocation.
Key Words: salivary, mammary analog secretory carcinoma,
MASC, ETV6-NTRK3, ETV6-RET fusion transcript
(Am J Surg Pathol 2017;00:000–000)
(Mammary analog) secretory carcinoma of salivarygland origin is a recently described tumor that
harbors a characteristic balanced t(12;15)(p13;q25) chro-
mosomal translocation resulting in an ETV6-NTRK3
fusion1 identical to that commonly found in secretory
carcinoma (SC) of the breast.2 The ETV6-NTRK3 fusion
gene encodes a chimeric tyrosine kinase with transforming
activity in epithelial and myoepithelial cells in the mouse
mammary gland.3
Over many years, Skalova et al1 began to identify
a distinctive, hitherto unrecognized neoplasm arising in
the salivary glands characterized by morphologic and
immunohistochemical features strongly reminiscent of
those of SC of the breast. These salivary carcinomas are
composed of microcystic and solid areas with abundant
vacuolated colloid-like periodic acid-Schiff-positive secre-
tory material within the microcystic spaces. These tumors
had previously been categorized as either unusual variants
of salivary acinic cell carcinoma (AciCC) or ad-
enocarcinoma not otherwise speciﬁed.1
Salivary SC was initially recognized as an entity
different from AciCC on the basis of 3 major ﬁndings.1
First, SC showed no basophilia in the cytoplasm of any of
the constituent cells, which is the hallmark of the serous
acinar cells of AciCC resulting from the presence of cy-
toplasmic zymogen granules. Second, these neoplasms had
a completely different immunohistochemical proﬁle, al-
most always expressing S100 protein, mammaglobin,
vimentin, STAT5, and MUC4, all of which are rarely
expressed in AciCC. Finally, SCs were found to harbor an
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ETV6-NTRK3 fusion gene due to a t(12; 15)(p13,q25)
translocation, a ﬁnding identical to SC of the breast2
and absent in AciCCs.1 Because of the morphologic
similarities and identical ETV6-NTRK3 fusion transcripts,
the designation “mammary analog secretory carcinoma of
salivary gland” has been proposed,1 and the name was
widely accepted and used in the literature. The most recent
version of the World Health Organization Classiﬁcation of
Head and Neck Tumors, however, utilizes the terminology
“secretory carcinoma”4 for consistency, and because SCs
have been recently described at other extrasalivary and
extramammary sites, such as thyroid gland,5–8 skin,9,10 and
sinonasal mucosa.11
The presence of the ETV6-NTRK3 fusion gene has not
been demonstrated in any other salivary gland tumor, but
the same translocation can be seen not only in SC of breast,2
but also in infantile ﬁbrosarcoma,12 congenital mesoblastic
nephroma,13 certain hematopoietic malignancies,14 ALK-
negative inﬂammatory myoﬁbroblastic tumors,15 a small
subset of gastrointestinal stromal tumors,16 and in radia-
tion-induced papillary thyroid carcinomas.17 Moreover,
ETV6-NTRK3 translocated papillary thyroid cancers have
been recently described in adult patients with no history of
radiation exposure.18
The near 100% rate of ETV6 gene rearrangement in SC
has been subsequently conﬁrmed by many other studies.19–25
Detection of ETV6 rearrangements by ﬂuorescent in situ
hybridization (FISH) or the ETV6-NTRK3 fusion by reverse-
transcriptase polymerase chain reaction (RT-PCR) in for-
malin-ﬁxed parafﬁn-embedded (FFPE) material is technically
relatively straightforward and >300 cases of SC have been
published since its original description.
Up until now, in all published cases of SC where the
fusion partner is identiﬁed, ETV6 is fused with NTRK3,
and no other fusion partners have been reported so
far. Nevertheless, for several years, we have been aware of
several SC cases positive for the ETV6 gene split as
visualized by FISH, but in which the classic ETV6-NTRK3
fusion transcript (exon 5-exon 15 junction) was not
detected by standard RT-PCR. A subset of SCs showing
ETV6 rearrangements with so far unknown partners have
been recently reported and provisionally called ETV6-X
translocated SCs,26 in agreement with a study of Ito
et al,27 who found 2 such cases. In the present study using
the next-generation sequencing (NGS) as a diagnostic
platform, we describe 10 cases morphologically and
immunohistochemically typical of SC, harboring a novel
ETV6-RET translocation.
MATERIALS AND METHODS
Among > 4500 cases of primary salivary gland tu-
mors, 194 cases of SCs were retrieved from the con-
sultation ﬁles of the Salivary Gland Tumor Registry, at
TABLE 1. Antibodies Used for Immunohistochemical Study
Antibody Speciﬁcity Clone Dilution Antigen Retrieval/Time (min) Source
S100 protein Polyclonal RTU CC1/20 Ventana
CK7 OV-TL 12/30 1:200 CC1/36 Dako Cytomation
GCDFP-15 EP1582y RTU CC1/64 Cell Marque
Mammaglobin 304-1A5 RTU CC1/36 Dako Cytomation
STAT 5a Polyclonal 1:400 CC1/36 Assay Designs Inc.
Ki-67 30-9 RTU CC1/64 Ventana
P63 4A4 RTU CC1/64 Ventana
DOG1 SP31 RTU CC1/36 Cell Marque
GATA3 L50-823 1:200 CC1/52 BioCare Medical
SOX10 Polyclonal 1:100 CC1/64 Cell Marque
CC1 indicates EDTA buffer, pH 8.6; RTU, ready to use (prediluted).
TABLE 2. Primers for Detection of ETV6-NTRK3 Fusion Transcripts
Original Primer Name Sequence Annealing Temperature (°C) Localization
ETV6-ex4-F3 AGCCGGAGGTCATACTGCAT 55 ETV6 exon 4 inner
ETV6-ex4-F4 CATTCTTCCACCCTGGAAAC 55 ETV6 exon 4 outer
ETV6B† ACATCATGGTCTCTGTCTCCCCGC 55 ETV6 exon 5 inner
TEL971* (ETV6A†) ACCACATCATGGTCTCTGTCTCCC 65 ETV6 exon 5 outer
NTRK3-ex14-R1 GTGATGCCGTGGTTGATGT 55 NTRK3 exon 14 inner
NTRK3 ex14-R2 AGTCATGCCAATGACCACAG 55 NTRK3 exon 14 outer
NTRK3B† TTCTCGCTTCAGCACGATGTCT 55 NTRK3 exon 15 inner
TRKC1059* (NTRK3A†) CAGTTCTCGCTTCAGCACGATG 65 NTRK3 exon 15 outer
ETV6-Archer1-F1 CGATGGGAGGACAAAGAATC 55 ETV6 exon 6
RET-Archer1-R1 AACCAAGTTCTTCCGAGGGA 55 RET exon 12
ETV6-Archer1-F2 CAACGGACTGGCTCGACTG 55 ETV6 exon 6
RET-Archer1-R2 GACCACTTTTCCAAATTCGCCT 55 RET exon 12
*Bourgeois et al32
†Ito et al,27 Skalova et al26.
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the Department of Pathology, Faculty of Medicine in
Plzen, and Biopticka Laborator Ltd, Plzen, Czech Re-
public (A.S. and M.M.).
The histopathologic features of all tumors and the
immunohistochemical stains, when available, were re-
viewed by 2 pathologists (A.S. and M.B.). A diagnosis of
SC was conﬁrmed in cases that displayed, at least focally,
histologic features consistent with original description1 in
conjunction with the appropriate immunohistochemical
proﬁle, that is, coexpression of S100 protein, cytokeratin
CK7, and mammaglobin with the absence of p63 and
DOG1 staining. For the purpose of this particular study,
we have included 4 cases of SC with ETV6-X proﬁle from
study Skalova et al26 and 26 cases of SC with ETV6 gene
break found by FISH or with morphologic and im-
munohistochemical pattern of SC but without analyzable
ETV6 gene break by FISH due to low quality or lack of
material. Thus, a total of 30 SC cases were studied by
NGS using ArcherDX Fusion Plex Kit.
For conventional microscopy, the excised tissues
were ﬁxed in formalin, routinely processed, embedded in
parafﬁn (FFPE), cut, and stained with hematoxylin and
eosin. In most cases, additional stains were also per-
formed, including periodic acid-Schiff with and without
diastase, mucicarmine, and alcian blue at pH 2.5.
For immunohistochemical studies, 4 μm thick sec-
tions were cut from parafﬁn blocks and mounted on
positively charged slides (TOMO, Matsunami Glass Ind.,
Japan). Sections were processed on a BenchMark UL-
TRA (Ventana Medical System, Tucson, AZ), deparafﬁ-
nized, and then subjected to heat-induced epitope retrieval
by immersion in a CC1 solution at pH 8.6 at 95°C. After
antigen retrieval, sections were stained with a pan-
RTK antibody cocktail consisting of rabbit monoclonal
antibodies, all obtained from Cell Signaling (Danvers,
MA), targeting pan-Trk (A7H6R, active against TrkA,
TrkB, and TrkC, 1:50 dilution), ROS1 (D4D6, 1:50), and
ALK (D5F3, 1:50), as described previously.28
All other primary antibodies used are summarized in
Table 1. The bound antibodies were visualized using the
ultraView Universal DAB Detection Kit (Roche) and
ultraView Universal Alkaline Phosphatase Red Detection
Kit (Roche). The slides were counterstained with the
Mayer hematoxylin. Appropriate positive and negative
controls were used.
Clinical follow-up was obtained from the patients,
their physicians, or from referring pathologists.
Molecular Genetic Study
Detection of ETV6-NTRK3 and ETV6-RET Fusion
Transcripts by RT-PCR
RNA was extracted using the RecoverAll Total
Nucleic Acid Isolation Kit (Ambion, Austin, TX). cDNA
was synthesized using the Transcriptor First Strand cDNA
Synthesis Kit (RNA input 500 ng; Roche Diagnostics,
Mannheim, Germany). All procedures were performed
according to the manufacturer’s protocols. Ampliﬁcation
of a 105 and 133 bp product of the μ2-microglobulin gene
and 247 bp product of the PGK gene was used to test the
quality of the extracted RNA as previously described.29–31
A detection of classic exon 5 of ETV6 gene and exon 15 of
NTRK3 gene,32 as well as atypical exon 4 of the ETV6
gene and exon 14 of the NTRK3 gene (and their combi-
natorial variants) fusion transcript was performed by
RT-PCR. In addition, more sensitive, nested RT-PCR
was performed for the detection of classic26,27 as well
as selected atypical junction of transcripts. Except that,
FIGURE 1. A, The result of analysis by NGS with custom-designed ArcherDX Kit of case 3 (case 17 in Skalova et al26). Analysis
revealed the presence of fusion transcript ETV6-RET joining exons 6 and 12, respectively. The red arrows represent position of
primers. B, The confirmation of the presence of ETV6-RET fusion transcript by RT-PCR followed by Sanger sequencing. The black
arrow indicates area of fusion.
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RT-PCR for ETV6-RET fusion transcript detection was
also carried out after receiving of the NGS results.
For single-round PCR, 2 L of cDNA was added
to reaction consisting of 12.5 μL of HotStar Taq PCR
Master Mix (QIAgen, Hilden, Germany), 10 pmol of each
primer (Table 2), and distilled water up to 25 μL. The
ampliﬁcation program comprised denaturation at 95°C
for 14 minutes and then 45 cycles of denaturation at 95°C
for 1 minute, annealing at temperature seen in Table 2 for
1 minute and extension at 72°C for 1 minute. The program
was ﬁnished by incubation at 72°C for 7 minutes. For
nested PCR, the same reaction conditions were utilized.
One microliter of PCR product from the ﬁrst round was
used as a template.
Successfully ampliﬁed PCR products were puriﬁed
with magnetic particles of Agencourt AMPure (Agencourt
Bioscience Corporation, A Beckman Coulter Company,
Beverly, MA). Products were then bidirectionally
sequenced using Big Dye Terminator Sequencing Kit
(Applied Biosystems, Foster City, CA), and puriﬁed with
magnetic particles of Agencourt CleanSEQ (Agencourt
Bioscience Corporation), all according to the manufacturer’s
protocol, and run on an automated sequencer ABI Prism
3130xl (Applied Biosystems) at a constant voltage of 13.2 kV
for 11 minutes.
Detection of Alteration of ETV6, NTRK3, and RET
Genes by FISH Method
Four-micrometer-thick FFPE sections were placed
onto positively charged slides. Hematoxylin and eosin–
stained slides were examined for determination of areas
for cell counting.
FIGURE 2. Interphase FISH analysis using break-apart probes (A–C) and dual-fusion probe (D). Positive cells with break-apart ETV6
(A) and RET (C) probes contain nucleus with separate (split) orange and (or) green signals indicating a rearrangement (break) of 1
copy of the gene region and also 1 orange/green (yellow) fusion signal representing 1 normal (intact) copy of homolog locus.
Negative cells with break-apart NTRK3 (B) probe contain only normal (not split) yellow signal. Positive cells using fusion probe
ETV6-RET (D) show orange/green (yellow) fusion signals representing translocation ETV6-RET and also separate orange and green
signals showing the intact genes.
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The unstained slides were routinely deparafﬁnized
and incubated in the ×1 Target Retrieval Solution Citrate
pH 6 (Dako, Glostrup, Denmark) at 95°C for 40 minutes
and subsequently cooled for 20 minutes at room temper-
ature in the same solution. Slides were washed in de-
ionized water for 5 minutes and digested in protease
solution with Pepsin (0.5 mg/mL; Sigma Aldrich, St Louis,
MO) in 0.01M HCl at 37°C for 25 to 60 minutes,
according to the sample conditions. Slides were then
placed into deionized water for 5 minutes, dehydrated in a
series of ethanol solutions (70%, 85%, 96% for 2 min
each), and air dried.
Two commercial probes were used for the detection
of rearrangement of ETV6 and RET genes, Vysis ETV6
Break Apart FISH Probe Kit (Vysis/Abbott Molecular,
IL) and ZytoLight SPEC RET Dual Color Break Apart
Probe (ZytoVision GmbH, Bremerhaven, Germany).
ETV6 probe was mixed with water and LSI/WCP (Locus-
Speciﬁc Identiﬁer/Whole Chromosome Painting) Hybrid-
ization buffer (Vysis/Abbott Molecular) in a 1:2:7 ratio,
respectively. RET probe was factory premixed.
Probes for detection of rearrangement ofNTRK3 gene
region and ETV6-RET genes fusion were mixed from cus-
tom designed SureFISH probes (Agilent Technologies Inc.,
Santa Clara, CA). Chromosomal regions for NTRK3
break-apart probe oligos are chr15:87501469-88501628 and
chr15:88701444-89700343; for ETV6-RET fusion probe,
chr12:11675872-12175711 and chr10:43354893-43849282.
Probe mixture was prepared from corresponding probes
(each color was delivered in a separate well), deionized
water, and LSI Buffer (Vysis/Abbott Molecular) in a 1:1:1:7
ratio, respectively.
An appropriate amount of mixed and premixed
probes was applied on specimens, covered with a glass
coverslip, and sealed with rubber cement. Slides were
incubated in the ThermoBrite instrument (StatSpin/Iris
Sample Processing, Westwood, MA) with codenaturation
at 85°C for minutes and hybridization at 37°C for hours.
Rubber cemented coverslip was then removed and the
slide was placed in posthybridization wash solution
(2×SSC/0.3% NP-40) at 72°C for 2 minutes. The slide was
air dried in the dark, counterstained with 4′,6′-diamidino-
2-phenylindole DAPI (Vysis/Abbott Molecular), cover-
slipped, and immediately examined.
FISH Interpretation
The sections were examined with an Olympus BX51
ﬂuorescence microscope (Olympus Corporation, Tokyo,
Japan) using a ×100 objective and ﬁlter sets Triple
Band Pass (DAPI/SpectrumGreen/SpectrumOrange),
Dual Band Pass (SpectrumGreen/SpectrumOrange), and
Single Band Pass (SpectrumGreen or SpectrumOrange).
TABLE 3. Molecular Genetics Findings in 10 Cases of SC With ETV6-RET Fusion
Case # Case #
NGS
Results Fusion
FISH
ETV6ba
FISH
NTRK3ba
RT-PCR
ETV6-NTRK3
FISH
RETba
FISH
ETV6-RET
RT-PCR
ETV6-RET
1 6* + ETV6-RET + − − + + +
2 15* + ETV6-RET + − − + ND +
3 17* + ETV6-RET + − − + + +
4 20* + ETV6-RET + − − + + −
5 + ETV6-RET + − − + + +
6 + ETV6-RET ND ND − ND + +
7 + ETV6-RET + − − + + +
8 + ETV6-RET NA NA − NA + +
9 + ETV6-RET ND ND − ND ND −
10 12† + ETV6-RET + − − + + +
*Skalova et al26 (Table 6).
†Stevens et al8 (Table 2).
NA indicates not analyzable; ND, not done due to lack of material.
TABLE 4. Details of NGS Analysis by the Archer Platform in 10 Cases of SC With ETV6-RET Translocation
Case # Case #
NGS
Results Fusion
Exons Included in
Fusion
No. Valid Fusion
Read
% of Reads Supporting
Fusion
No. Unique Start
Sites
1 Case 6* + ETV6-RET 6-12 51 100 17
2 Case 15* + ETV6-RET 6-12 84 20.1 33
3 Case 17* + ETV6-RET 6-12 1126 23.5 183
4 Case 20* + ETV6-RET 6-12 15 1.8 10
5 + ETV6-RET 6-12 163 11.4 63
6 + ETV6-RET 6-12 21 100 11
7 + ETV6-RET 6-12 49 14 32
8 + ETV6-RET 6-12 100 86.2 51
9 + ETV6-RET 6-12 41 60.3 14
10 Case 12† + ETV6-RET 6-12 24 14.8 17
*Skalova et al26 (Table 6).
†Stevens et al8 (Table 2).
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For each probe, 100 randomly selected nonoverlapping
tumor cell nuclei were examined for the presence of yellow or
green and orange ﬂuorescent signals. Regarding break-apart
probes, yellow signals were considered negative, and separate
orange and green signals were considered positive; conversely,
for fusion probe, yellow signals were considered positive,
and separate orange and green signals were considered
negative.
Cutoff values were set to > 10% and 20% of nuclei
(break-apart and fusion probes, respectively) with chro-
mosomal breakpoint signals (mean, +3 SD rounded up in
normal non-neoplastic control tissues).
Sample Preparation for NGS
For NGS studies, 2 to 3 FFPE sections (10 µm thick)
were macrodissected to isolate tumor-rich regions. Sam-
ples were extracted for total nucleic acid using Agencourt
FormaPure Kit (Beckman Coulter, Brea, CA) following
the corresponding protocol with an overnight digest and
an additional 80°C incubation as described in mod-
iﬁcation of the protocol by ArcherDX (ArcherDX Inc.,
Boulder, CO). Total nucleic acid was quantiﬁed using the
Qubit Broad Range RNA Assay Kit (Thermo Fisher
Scientiﬁc) and 2 µL of sample.
RNA Integrity Assessment and Library Preparation
for NGS
Unless otherwise indicated, 250 ng of FFPE RNAwas
used as input for NGS studies. To assess RNA quality, the
PreSeq RNA QC Assay using iTaq Universal SYBR Green
Supermix (Biorad, Hercules, CA) was performed on all
samples during library preparation to generate a measure of
the integrity of RNA (in the form of a cycle threshold
value). Library preparation and RNA QC were performed
following the Archer Fusion Plex Protocol for Illumina
(ArcherDX Inc.). A custom primer set with 28 primers
spanning regions on 3 speciﬁc genes of interest, including all
8 exons of ETV6 gene in 3′ direction, was designed and
used. Final libraries were diluted 1:100,000 and quantiﬁed
in a 10 µL reaction following the Library Quantiﬁcation
for Illumina Libraries protocol and assuming a 200 bp
fragment length (KAPA, Wilmington, MA). The concen-
tration of ﬁnal libraries was around 200 nM. The threshold
representing the minimum molar concentration for which
sequencing can be robustly performed was set at 50 nM.
NGS and Analysis
Libraries were sequenced on a MiSeq sequencer
(Illumina, San Diego, CA). They were diluted to 4 nM and
equal amounts of up to 16 libraries were pooled per
run. The optimal number of raw reads per sample was set
to 500,000. Library pools were diluted to 16 pM library
stock with 5% 12.5 pM PhiX and loaded into the MiSeq
cartridge. Analysis of sequencing results was performed
using the Archer Analysis software (v5; ArcherDX Inc.).
Fusion parameters were set to a minimum of 5 valid
fusion reads with a minimum of 3 unique start sites within
the valid fusion reads.
RESULTS
Molecular Genetic Findings
Selected 30 cases of SC (as described earlier) were
analyzed by NGS using the ArcherDX analysis platform.
TABLE 5. Clinical Findings in 10 SCs With ETV6-RET Fusion Transcript
Case #
Age/
Sex Case # Stadium TNM
Local
Recurrence
Length of
Symptoms
Metastasis
(y, mo) Treatment
Follow-
up Outcome
1 50/M Case 6* NA NA NA NA NA NA
2 29/M Case 15* pT2pN1M0 No 6 y LN+ SP and RT, no neck
dissection
4 y 6
mo
Alive NED
3 31/M Case 17* pT3pN0M0 Residual
tumor
7 y No Excision radical
resection (1 mo)
4 y Alive NED
4 77/F Case 20* pT2N0M0 No 1 y No Excision, RT 3 y DOC
5 51/M pT3N0M0 Residual
tumor
15mo No Excision SP after
3 mo
8mo Alive NED
6 20/F pT3N0M0 No NA No PE NA NA
7 55/M pT3N0M3 No 3 y Multiple bone meta
(pelvic, scapula)
at 15 mo
PP, RT, and CHT 2 y DOD
8 28/F pT1N0M0 No 1mo No Parotid resection and
lymphadenectomy
level II: 12 lymph
nodes negative
2 y Alive NED
9 33/M pT1pN0 (0/2) No 6mo No PP 3 y 9
mo
Alive NED
10 34/M Case 12† pT2N0M0 (0/1) No Several months,
very slow
enlargement
No SP 4 y 2
mo
Alive NED
*Skalova et al26 (Table 6).
†Stevens et al8 (Table 2).
CHT indicates chemotherapy; DOC, dead of other causes; DOD, dead of disease; LN, lymph nodes; NA, not available; NED, no evidence of disease; PE, parotidectomy;
PP, partial parotidectomy; RT, radiotherapy; SP, superﬁcial parotidectomy.
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This analysis detected a novel ETV6-RET fusion tran-
script joining exon 6 of ETV6 gene and exon 12 of RET
gene in 10 cases of salivary gland tumors displaying
histologic and immunohistochemical features typical of
SC (Fig. 1). All but 1 ETV6-RET positive SC case were
then tested by at least 1 FISH probe for the presence
of ETV6-RET rearrangements (Fig. 2). In case 9, there
was no residual tissue material for conﬁrmation of
the NGS analysis by FISH tests. In addition, RT-PCR
for the conﬁrmation of the presence of ETV6-RET fusion
transcript followed by Sanger sequencing on positive
samples was performed in all 10 cases (Fig. 1). The results
of the NGS tests, details of the analysis, and results of
conﬁrmatory genetic tests are summarized in Tables 3 and
4. In addition, NGS analysis resulted in detection of the
ETV6-NTRK3 fusion in 15 SC cases. In 4 cases, NGS
revealed negative results, and 1 case was unanalyzable
(detailed data not shown). No other fusion transcripts
different from ETV6-NTRK3 or ETV6-RET were found
by NGS in any analyzable case of SC.
Clinical and Histologic Characteristics of the
Study Group
The clinical and follow-up data of 10 patients
with ETV6-RET translocated SC of salivary glands are
summarized in Table 5. There were 3 female and 7 male
patients. The median patient age was 40.8 years, with a range
between 20 and 77 years. The most common anatomic site of
involvement was the parotid gland, occurring in 7 patients.
Other primary sites of the origin included the submandibular
gland and minor salivary gland of the upper lip in 2 patients
and 1 patient, respectively.
Follow-up Data
Clinical follow-up data were obtained from 8 patients,
and ranged from 6 to 50 months (mean, 36mo); 2 patients
were lost to follow-up. Detailed clinical, follow-up, and
histologic ﬁndings in 10 patients with ETV6-RET trans-
located SC are summarized in Table 5.
All tumors were treated by surgical excision; in
1 patient the excision was radical with clear surgical
margins, in 4 cases the surgical margins were positive, and
in 4 additional patients, the tumor inﬁltration was close
(< 0.5 mm) to the surgical margins. Five patients under-
went subtotal conservative parotidectomy, in 3 of them
in combination with radiotherapy (cases 2, 4, and 7).
Residual tumors were treated by radical reexcision
with clear surgical margins in 2 patients. Concomitant
chemotherapy and radiotherapy was used in 1 patient with
high-grade transformed SC complicated by metastatic
TABLE 6. Clinical and Histologic Findings in 10 SCs With ETV6-RET Fusion Transcript
Case
#
Age/
Sex
Case
# Location
Tumor
Size
(mm) Capsule
Surgical
Margins
Thick
Fibrous
Septa
Hyalinized
Sclerosis
Invasion
(LVI, PN)
Cystic
Pattern Necrosis Comments
1 50/M Case
6*
Lip 15 NA 2 No No NA No − Fragmented
tissue
2 29/M Case
15*
Parotid 23 No 1 + ++ PN+, LVI
+Extraglandular,
muscle invasion
No − Hyalinized,
multilobular,
microcystic,
and solid
growth pattern
3 31/M Case
17*
Submand 30 No 2 ++ ++ PN+ No − Hyalinized,
multilobular,
microcystic
4 77/F Case
20*
Submand 70 Focal + + No + − Multicystic,
papillary with
apocrine cells
5 51/M Parotid 10 No 1 ++ ++ PN+ No + Central
hyalinized
sclerosis,
invasive growth
pattern
6 20/F Parotid 40 No 2 + + Extraglandular No − Lobular,
microcystic
7 55/M Parotid 70 No 2 + + PN+,
perivascular
+ + High grade
component
8 28/F Parotid 12 No 1 + + Intraglandular No − Predominantly
solid and
microcystic
9 33/M Parotid 17 + 1 No No No + − Predominantly
cystic
10 34/M Case
12†
Parotid 19 + 0 No No No + − Multicystic with
mural nodules
*Skalova et al26 (Table 6).
†Stevens et al8 (Table 2).
Surgical margins: free-0; close (means distance from the tumor <0.5 mm ) -1; positive-2.
F indicates female; LVI, lymphovascular invasion; M, male; NA, not available; PN, perineural invasion.
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disease at 15 months after surgery (case 7). Clinical and
follow-up ﬁndings are summarized in Table 5.
Macroscopic Features
Detailed clinical and morphologic ﬁndings in 10
patients with ETV6-RET translocated SC are summarized
in Table 6. The median tumor size was 3.6 cm, with a
range of 1.0 to 7.0 cm. Grossly, most tumors were variably
invasive: 2 were entirely circumscribed and encapsulated,
1 had focally inﬁltrative edges, and 7 were predominantly
inﬁltrative.
Microscopic and Immunohistochemical Features
On low power magniﬁcation, 3 major growth
patterns of SC were identiﬁed in our material. First, 3
tumors were well circumscribed and surrounded by a
thick, focally uninterrupted, ﬁbrous capsule enclosing a
predominantly multicystic growth pattern with multiple
mural nodules (Fig. 3A). The cysts were lined mostly by a
single or focally by a double layer of cells with prominent
apocrine differentiation including hobnail and vacuolated
foamy cells (Figs. 3B, C), and contained abundant
proteinaceous eosinophilic material. The ﬁbrous capsule
and septa comprised psammomatoid calciﬁcations in some
places (Fig. 3D). The second pattern was characterized by
solid and microcystic growth with a multilobular structure
divided by thin ﬁbrous septa (Fig. 4A). The tumors either
lacked a capsule or were only partially encapsulated with
prominent inﬁltrative borders (Fig. 4B). These cases were
predominantly composed of microcystic and slightly
dilated glandular spaces ﬁlled with a variable amount of
eosinophilic homogenous secretory material (Fig. 4C).
The third pattern, prevailing in 3 cases, comprised a
prominent ﬁbrosclerotic stroma with isolated tumor cells
in small islands or trabeculae, which were seen in the
central part of the tumor (Fig. 5A). In case 7, 2 different
growth patterns were seen, in particular low-grade
components arranged in multiple macrocystic and
microcystic lobules with comedo-like necroses, and high-
grade components with limited secretory material and
high proliferative activity (Fig. 5B).
However, most tumors demonstrated 2 or more ar-
chitectural patterns, with microcystic, tubular, solid, and
papillary patterns often occurring together. Regardless of
FIGURE 3. A, SC is well circumscribed and surrounded by a thick fibrous capsule enclosing predominantly multicystic growth
pattern with multiple mural nodules. The cysts were lined mostly by a single or focally by a double layer of cells with prominent
apocrine differentiation including hobnail (B) and vacuolated foamy cells (C). The fibrous capsule and septa comprised psammoma
bodies in places (D).
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the growth pattern of SC, the tumor cells were often bland
looking, with abundant pale pink vacuolated and foamy
cytoplasm and with vesicular oval nuclei with a single
small but prominent nucleolus. The cytologic features
were similar from case to case. The range of nuclear atypia
was assessed as grades 1 to 3. Mitotic ﬁgures were rare and
necrosis was absent. Prominent perineural and intraneural
invasion was seen in case 7 (Fig. 5C). Only 1 patient
(case 2) presented with a single periparotideal lymph node
metastasis at the time of diagnosis.
Immunohistochemical Findings
By immunohistochemistry, all examined SC cases
were positive for S100 protein (Fig. 6A), mammaglobin
(Fig. 6B), typically in strong and diffuse fashion (secretory
material was also positive), and cytokeratin CK7
(Fig. 6C). GATA-3, SOX-10 (Fig. 6D), and STAT5a
expression was detected in 3/6, 5/6, and 2/3 cases,
respectively. P63 protein was completely negative in most
cases, with limited areas of positive peripheral myoepithelial
cell staining suggestive of a focal intraductal component
in 3 cases. DOG1 was negative in all examined cases.
Proliferative activity was generally low, with a mean MIB1
index of 15% (range, 5% to 40%).
DISCUSSION
Salivary gland tumors are increasingly being found
to have characteristic chromosomal rearrangements. SC
is a salivary gland tumor that recapitulates the histology
and genetics of a rare malignancy of the breast SC.
These tumors are deﬁned by the t(12;15)(q13;q15) trans-
location, a fusion of the ETV6 gene from chromosome
12 and the NTRK3 gene from chromosome 15. The
same translocation has been detected in most cases
of the infantile ﬁbrosarcomas, congenital mesoblastic
nephromas,13 chronic eosinophilic leukemias,33 acute
myeloid leukemia,14 and some papillary carcinomas
of the thyroid with and without previous irradiation.18
These groups of tumors are the focus of interest,
because tumors with ETV6-NTRK3 fusion translocation
respond well to treatment by entrectinib, which is a potent
inhibitor of tyrosine kinases TRKA/B/C, ROS1, and
ALK. The drug entrectinib is administered orally, is safe
and well tolerated, and can cross the blood-brain barrier,
FIGURE 4. A, SC is characterized by solid and microcystic growth with a multilobular structure divided by thin fibrous septa. B, The
tumor has a prominent infiltrative border. C, The tumor is predominantly composed of microcystic and slightly dilated glandular
spaces filled with a variable amount of eosinophilic homogenous secretory material.
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so that it can be effective for treatment of brain
metastases.34,35
Originally it appeared that all cases of SC share
the same ETV6-NTRK3 fusion translocation. However, in
recent years Ito et al27 and Skalova et al26 described alto-
gether 6 cases of SC with the ETV6 gene split detected by
FISH, but in which the ETV6 gene appeared to be fused
with a gene different to NTRK3. These cases were marked
as SCs with ETV6-X fusion.
Herein, we describe a novel ETV6-RET fusion in 10
cases of salivary gland carcinomas with histologic features
and IHC proﬁle typical of SC, including the 4 ETV6-X SC
cases published previously.26 The presence of ETV6-RET
fusion in SC was proven by at least 3 independent tests
(NGS, FISH, RT-PCR), in all but 2 cases (Table 3, cases 4
and 9). In case 4, NGS and FISH conﬁrmed ETV6-RET
fusion but RT-PCR was negative, probably due to low or
focal expression of fusion transcript (Table 4). Case 9 was
the only sample unconﬁrmed by independent analysis.
There was a lack of material for FISH analysis and
RT-PCR for ETV6-RET fusion transcript detection was
negative. In this case, low quality of RNA rather than low
or focal expression is responsible for this result.
The alternative ETV6-RET transcription will be
important for treatment of those SCs with uncontrolled
regional growth or SCs with metastatic foci, as treatment
with entrectinib and similar drugs with the same target
speciﬁcity will probably be ineffective in these SCs with
alternative fusion transcript different from ETV6-NTRK3.
The alternative fusion partner different from ETV6-NTRK3
in SC should not be of great surprise, because infantile
ﬁbrosarcoma with ETV6-NTRK3 translocation may
have alternative EML4-NTRK3 translocation,36 and there
are descriptions of acute myeloid leukemias in which the
ETV6 gene fuses with many alternative fusion partners,
including ETV6-ABL1,37 ETV6-LPXN,38 ETV6-RUNX1,39
ETV6-NCOA2,40 and many others.
To our knowledge, ETV6-RET fusions have not
been reported in salivary gland tumors so far. Notably,
however, recent studies using RNA sequencing have
revealed that salivary duct carcinoma (SDC) may also be
added to the growing list of gene fusion-positive salivary
FIGURE 5. A, The third pattern of SC has a prominent fibrosclerotic stroma with isolated tumor cells in small islands or trabeculae
were seen in the central part of the tumor. B, High-grade component of SC with limited secretory material and high proliferative
activity. C, Prominent perineural and intraneural invasion was seen in 1 tumor.
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carcinomas. NCOA4-RET fusions have been found in
2 SDCs.41 Both NCOA4-RET translocated SDCs were
positive for androgen receptors, and the tumors progressed
in spite of undergoing concurrent chemoradiation, com-
bination chemotherapy, and dual androgen deprivation
therapy. Both patients with NCOA4-RET translocation,
however, beneﬁted from RET-targeted therapy.41
The treatment of SC has varied, ranging from simple
excision to radical resection, neck dissection, adjuvant ra-
diotherapy, and/or adjuvant systemic chemotherapy.1,42,43
For patients presenting with a locally advanced, recurrent,
or metastatic disease, the treatment options are currently
limited and mainly palliative.42,43 Therefore, SCs with
ETV6-RET fusion translocation must be clearly dis-
tinguished from SCs with ETV6-NTRK3 translocation,
because the drugs RXDX105 and LOXO 292, effective
with various tumors driven with RET gene alterations, are
being tested for the treatment. SCs with ETV6-RET
translocation might respond much better to these drugs,
whereas entrectinib and similar inhibitors of tyrosine kin-
ases TRKA/B/C will probably be ineffective.44–47
In summary, a novel ﬁnding in our study has been
the discovery of a subset of SC patients with ETV6-RET
fusions who may beneﬁt from RET-targeted therapy.
Many salivary gland malignancies are still included in
the group of adenocarcinomas not otherwise speciﬁed.
We believe that detailed genomic proﬁling and NGS of a
large cohort of these unspeciﬁed neoplasms may lead to the
identiﬁcation of novel gene fusions and driver mutations
characterizing new clinically relevant subgroups of salivary
gland carcinomas. This study highlights that further
molecular analyses of salivary gland tumors are warranted
and deserve special attention to identify new tumor types
with possible therapeutic implications.
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FIGURE 6. SC cases were all positive for S100 protein (A), mammaglobin (B), typically in strong and diffuse fashion (secretory
material was also positive), and cytokeratin CK7 (C). SOX-10 positive nuclear expression is present (D).
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